← Eichor
Study identifier: NCT06304389 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy

Condition: Refractory Epilepsy  ·  Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

PhaseNA
Planned participants34
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersYes

About this study

Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response. Light, and particularly blue light, can stimulate alertness, attention and cognition through modulation of anatomical targets which are common to the vagal afferent network. This project aims at understanding how exposure to blue enriched light may influence VNS effects in patients with refractory epilepsy by exploring the modulation of a series of biomarkers of VNS action. This could possibly lead to new therapeutic strategies to increase efficacy of VNS.

This description comes directly from the study's public registry record.

Talk to the study team

Inci cakiroglu  ·  +32470612917  ·  inci.cakiroglu@uclouvain.be

Always discuss trial participation with your own doctor first.

Locations (1)

Cliniques Universitaires Saint LucWoluwe-Saint-Lambert, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06304389